Abstract
Irsogladine maleate is a gastro-protective drug that is known to increase mucosal blood flow and facilitate gap junctional intracellular communication, leading to fortification of the tight junctions of the entire gastro-intestinal mucosa.
Highlights
Radiation proctitis occurs chronically in 5-20% of patients following pelvic radiotherapy for malignancies of the prostate, rectum, urinary bladder, cervix, uterus, and testes [1,2]
We report a case of radiation proctitis improved by oral administration of irsogladine maleate
This is the first case report in which irsogladine showed a clinical effect on a radiationinduced intestinal disorder
Summary
Yutaka Yamaji1*, Yoshihiro Isomura, Shuntaro Yoshida, Atsuo Yamada, Yoshihiro Hirata, Kenshiro Shiraishi, Jinpei Kumagai, Yutaka Enomoto, Yukio Homma and Kazuhiko Koike. Received: June 24, 2014; Accepted: August 26, 2014; Published: September 05, 2014
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Gastroenterology, Pancreatology & Liver Disorders
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
